Medic School drug Quiz. Up to and inculing Cardiac drugs.
Calcium Channel Blocker
Antidysrhythmic
Beta Blocker
Chlorinergic Adrenergic
Shock Resistant V-Fib, Pulseless V-Tach, Stable V-Tach.
Unstable V-Tach, V-Tach with Pulsess, V-Fib.
Shockable V-Fib, Pulseless V-tach, Unstable V-Tach.
Shock Resistant V-Tach, Pulseless V-tach, Unstable V-Tach
Bolus: 150 mg in 50 cc over 10 min. (60 gtts/cc at 10 gtts/min). 1 gtts/10 sec. Maintenance: 150 mg in 50 cc over 30 min. (60 gtts/cc at 20 gtts/min).
Bolus: 150 mg in 50 cc over 10 min. (10 gtts/cc at 60 gtts/min). 1 gtt/sec Maintenance: 150 mg in 50 cc over 10 min. (60 gtts/cc at 20 gtts/min) 1 gtt/3 sec.
Bolus: 300 mg in 50 cc over 10 min. ( 10 gtts/cc at 60 gtts/min). 1gtts/sec. Maintenance: 150 mg in 50 cc over 10 min. (60 gtts/cc at 20 gtts/min). 1 gtts/3 sec.
Bolus 300 mg slow IV: Maintenance 150 mg slow IV over 10 minutes
Unstable Angina, Acute Coronary Syndrome, STEMI.
Stable Angina, Acute Coronary Syndrome, STEMI
Unstable Angina, Chronic Coronary Syndrome, Hemorrhagic Stroke.
Stable Angina, Chronic Coronary Syndrome
161-324 mg
81-324 mg
81-325 mg
161-325 mg
Asprin allergy, active bleeding ulcer, hemorrhagic stroke, bleeding disorder.
Asprin allergy, active bleeding, STEMI, bleeding disorder.
Tachycardia, active bleeding, hemorrhagic stroke, bleeding disorder.
Hypotension, Asprin allergy, active bleeding ulcer, hemorragic stroke, bleeding disorder.
Natural Catecholamine
Electrolyte
Parasympathomimetic
Sympatholytic
Digitalis toxicity
Hypokalemia
Calcium channel blocker toxicity
AV Blocks
10-20 mg/kg slow IV
8-16 mg slow IV
8-16 mg/kg slow IV
20 mg/kg slow IV/IM
Naloxine
Dextrose
Nacl
Sodium Bicarb
Slow Ca+ channel blocker
Decreases Inotropic Response
Decreases Chonotropic Response
Increases Inotropic response
2nd or 3rd degree AV block. A-Fib/A-Flutter from Wolf Parkinson Wolfe Syndrome
A-Fib, A-Flutter, PSVT Multifocal Atrial Tachycardia Short P-R interval syndrome
A-Fib with PVCs with a ventricular response >150 A-Flutter with a 2:1 conduction with a ventricular response >150 Multifocal atrial tachycardia PSVT
A-Fib with Ventricular response > 150. A-Flutter with ventricular response >150 Multifocal atrial tachycardias. PSVT
Bolus .25 mg/kg (15-20 mg) IV over 2 min; repeat in 10 min at .35 mg/kg (20-25 mg) over 2 min.
Bolus .25 mg IV over 2 min; repeat in 10 min at .35 mg over 2 min.
Bolus 25 mg IV over 2 min; repeat in 10 min at 35 mg over 2 min.
Bolus 2.5 mg/kg (15-20 mg) IV over 2 min; repeat in 10 min at 3.5 mg/kg (20-25 mg) over 2 min.
Cardiac glycoside, Antidysrhythmic. Increased Vagel tone, Decreased SA rate, decreased sympathetic tone, decreased AV node conduction velocity
Elctrolyte, Antidysrhythmic. Decreases vagel tone, decreased SA rate, decreased sympathetic tone, decreased AV node conduction velocity.
Cardiac glycoside, antidysrhythmic. Decreased vagel tone, decreased SA rate, decreased sympathetic tone, decreased AV node conduction velocity.
Cardiac glycoside, antidysrythmic. Increased vagal tone, increased SA rate, increased sympathetic tone, increased AV node conduction velocity
Sympathomimetic. Stimulates beta 1 adrenergic receptors.
Sympathomimetic. stimulates beta 1 chlorinergic receptors
Parasympathomimetic. stimulates alpha 1 adrenergic receptors
Parasympatholytic. stimulates beta 1 chlorinergic receptors
2-20 mg/kg IV/IO
2-20 mg IV/IO
2-20 mcg IV/IO
2-20 mcg/kg/min IV/IO
Benzodiazapine
Opiod analgesic
Sympatholytic
Parasympatholytic
Pain control, Sedation for RSI
Pain control, neuromuscular blocker
Sedation for RSI, neuromuscular blocker
Sedation for RSI, burn injuries
1-3 mg IV/IM
1-3 mg/kg IV/IM
1-3 mcg IV/IM
1-3 mcg/kg IV/IM
Parasympathomimetic
Parasympatholytic
Sympathomimetic
Sympatholytic
Tachycardia sustained above 150. PEA. Asystole. Organophosphate poisoning.
Pulseless electrical Activity and Asystole.
Tachycardias, Asystole, PEA sustained above 100, organophosphate poisoning, Pre-RSI for Peds.
Hemodynacically significant bradycardia. Asystole.bradycardia PEA. Organophosphate Poisoning. Pre-RSI for Peds.
Bradycardia: 0.5 mg q 3-5 min. PEA or asystole: 1 mg IV/IO q 3-5 min. Anticholinesterase: 1-2 mg IV/IO q 5-15 min.
Bradycardia: 5 mg q 3-5 min. PEA or asystole: 1 mg IV/IO q 3-5 min. Anticholinesterase: 1-2 mg IV/IO q 5-15 min.
Bradycardia: 0.5 mg/kg q 3-5 min. PEA or asystole: 1 mg/kg IV/IO q 3-5 min. Anticholinesterase: 1-2 mg/kg IV/IO q 5-15 min.
Bradycardia: 0.5/kg mg q 3-5 min. PEA or asystole: 1 mg IV/IO q 3-5 min. Anticholinesterase: 1-2 mg IV/IO q 5-15 min.
Parasympathomimetic. Acts primarily on alpha 1 and beta 1 adrenergic receptors in a dose-dependent fashion.
Parasympathomimetic. Acts primarily on alpha 2 and beta 2 adrenergic receptors in a dose-dependent fashion.
Sympathomimetic. Acts primarily on alpha 1 and beta 1 adrenergic receptors in a dose-dependent fashion.
Sympatholytic. Acts primarily on alpha 2 and beta 2 adrenergic receptors in a dose-dependent fashion.
At Low dose, it acts on dopaminergic receptors causing renal, mesenteric and cerebral vascular dilation. At moderate dose, it stimulates beta-adrenergic receptors causing enhanced myocardial contractility, increased cardiac output and rise in BP. At high dose it has an alpha adrenergic effect producing peripheral arterial and venous constriction.
At Low dose, it stimulates beta-adrenergic receptors causing enhanced myocardial contractility, increased cardiac output and rise in BP. At moderate dose, it acts on dopaminergic receptors causing renal, mesenteric and cerebral vascular dilation At high dose it has an alpha adrenergic effect producing peripheral arterial and venous constriction.
At Low dose, it acts on dopaminergic receptors causing renal, mesenteric and cerebral vascular dilation. At moderate dose, it has an alpha adrenergic effect producing a peripheral arterial and venous constriction At high dose it stimulates beta-adrenergic receptors causing enhanced myocardial contractility, increased cardiac output and rise in BP.
At Low dose, it has an alpha adrenergic effect producing peripheral arterial and venous constriction. At moderate dose, it stimulates beta-adrenergic receptors causing enhanced myocardial contractility, increased cardiac output and rise in BP. At high dose it acts on dopaminergic receptors causing renal, mesenteric and cerebral vascular dilation.
Renal: 2-5 mcg/kg/min (flushes liver& Kidneys) Cardiac: 5-10 mcg/kg/min (+inotropic) Vasopressor: 10-20 mcg/kg/min (+chronotrop)
Cardiac: 2-5 mcg/kg/min (+inotropic) Renal: 5-10 mcg/kg/min (flushes liver & Kidneys) Vasopressor: 10-20 mcg/kg/min (+chonotrop)
Vasopressor: 2-5 mcg/kg/min (+chonotrop) Cardiac: 5-10 mcg/kg/min (+ inotropic) Renal 10-20 mcg/kg/min (flushes liver & Kidneys)
Renal: 2-5 mcg/kg/min (flushes liver & Kidneys) Vasopressor: 5-10 mcg/kg/min (+chonotrop) Cardiac: 10-20 mcg/kg/min (+inotropic)
Wait!
Here's an interesting quiz for you.